Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy

PLoS Pathogens

Volumn 8, Issue 1, 2012, Pages

  Tattermusch, Sonja ^a   Skinner, Jason A ^b   Chaussabel, Damien ^b,c   Banchereau, Jacques ^b,d   Berry, Matthew P ^e,f   McNab, Finlay W ^e   O'Garra, Anne ^e   Taylor, Graham P ^a   Bangham, Charles R M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^f IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAG PROTEIN; GAMMA INTERFERON; INTERFERON; PROTEIN P53; TAX PROTEIN; TAX PROTEIN, HUMAN T LYMPHOTROPHIC VIRUS 1; TAX PROTEIN, HUMAN T-LYMPHOTROPHIC VIRUS 1; TP53 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HTLV 1 ASSOCIATED MYELOPATHY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; LEUKOCYTE; MALE; MICROARRAY ANALYSIS; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; PATHOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TROPICAL SPASTIC PARAPARESIS; VIRUS CARRIER; CLINICAL TRIAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; VIROLOGY;

HUMAN T-LYMPHOTROPIC VIRUS 1;

FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE PRODUCTS, GAG; GENE PRODUCTS, TAX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERFERON TYPE I; LEUKOCYTES; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAPARESIS, TROPICAL SPASTIC; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857497003     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002480     Document Type: Article

References (62)

1. Nagai M, Osame M, (2003) Human T-cell lymphotropic virus type I and neurological diseases. J Neurovirol 9: 228-235.
2. Manel N, Battini JL, Taylor N, Sitbon M, (2005) HTLV-1 tropism and envelope receptor. Oncogene 24: 6016-6025.
3. Bangham CR, (2000) The immune response to HTLV-I. Curr Opin Immunol 12: 397-402.
4. Iwasaki Y, Ohara Y, Kobayashi I, Akizuki S, (1992) Infiltration of helper inducer lymphocytes-T heralds central-nervous-system damage in Human T-cell Leukemia-Virus infection. Am J Pathol 140: 1003-1008.
5. Hauser SL, Oksenberg JR, (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52: 61-76.
6. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, et al. (1998) Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 4: 586-593.
7. Goon PKC, Hanon E, Igakura T, Tanaka Y, Weber JN, et al. (2002) High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Blood 99: 3335-3341.
8. Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CRM, (2008) High frequency of CD4(+)FoxP3(+) cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood 111: 5047-5053.
9. Yu F, Itoyama Y, Fujihara K, Goto I, (1991) Natural-killer (NK) cells in HTLV-I-associated myelopathy tropical spastic paraparesis- decrease in NK cell subset populations and activity in HTLV-I seropositive individuals J Neurovirol 33: 121-128.
10. Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, et al. (2002) Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 99: 88-94.
11. Meekings KN, Leipzig J, Bushman FD, Taylor GP, Bangham CR, (2008) HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog 4: e1000027.
12. Berry MPR, Graham CM, McNab FW, Xu ZH, Bloch SAA, et al. (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973-U998.
13. Pascual V, Chaussabel D, Banchereau J, (2010) A genomic approach to human autoimmune diseases. Annu Rev Immunol 28: 535-571.
14. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, et al. (2007) Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109: 2066-2077.
15. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG, (1990) Invivo cellular tropism of Human T-cell Leukemia-Virus Type-1. J Virol 64: 5682-5687.
16. Oliere S, Hernandez E, Lezin A, Arguello M, Douville R, et al. (2010) HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog 6: e1001177.
17. Fung MM, Chu YL, Fink JL, Wallace A, McGuire KL, (2005) IL-2- and STAT5-regulated cytokine gene expression in cells expressing the Tax protein of HTLV-1. Oncogene 24: 4624-4633.
18. Suzuki S, Zhou Y, Refaat A, Takasaki I, Koizumi K, et al. (2010) Human T Cell Lymphotropic Virus 1 Manipulates Interferon Regulatory Signals by Controlling the TAK1-IRF3 and IRF4 Pathways. J Biol Chem 285: 4441-4446.
19. Baba M, Okamoto M, Hamasaki T, Horai S, Wang X, et al. (2008) Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells. J Virol 82: 3843-3852.
20. Rahman S, Khan ZK, Wigdahl B, Jennings SR, Tangy F, et al. (2011) Murine FLT3 ligand-derived dendritic cell-mediated early immune responses are critical to controlling cell-free human T cell leukemia virus type 1 infection. J Immunol 186: 390-402.
21. Refaat A, Zhou Y, Suzuki S, Takasaki I, Koizumi K, et al. (2011) Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9. J Biol Chem 286: 21092-21099.
22. Bangham CR, Meekings K, Toulza F, Nejmeddine M, Majorovits E, et al. (2009) The immune control of HTLV-1 infection: selection forces and dynamics. Front Biosci 14: 2889-2903.
23. Jeffery KJM, Usuku K, Hall SE, Matsumoto W, Taylor GP, et al. (1999) HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A 96: 3848-3853.
24. Zhang L, Zhi H, Liu M, Kuo YL, Giam CZ, (2009) Induction of p21(CIP1/WAF1) expression by human T-lymphotropic virus type 1 Tax requires transcriptional activation and mRNA stabilization. Retrovirology 6: 35.
25. Krueger A, Fas SC, Giaisi M, Bleumink M, Merling A, et al. (2006) HTLV-1 tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 107: 3933-3939.
26. Mochizuki M, Tajima K, Watanabe T, Yamaguchi K, (1994) Human T lymphotropic virus type 1 uveitis. Br J Ophthalmol 78: 149-154.
27. Gandhi KS, McKay FC, Cox M, Riveros C, Armstrong N, et al. (2010) The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Gen 19: 2134-2143.
28. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, et al. (2008) A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus. Immunity 29: 150-164.
29. Guerreiro JB, Santos SB, Morgan DJ, Porto AF, Muniz AL, et al. (2006) Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Clin Exp Immunol 145: 296-301.
30. Narikawa K, Fujihara K, Misu T, Feng J, Fujimori J, et al. (2005) CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-alpha. J Neuroimmunol 159: 177-182.
31. Hall JC, Rosen A, (2010) Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 6: 40-49.
32. Randall RE, Goodbourn S, (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1-47.
33. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ, (2009) INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res 37: D852-857.
34. Harris JM, Chess RB, (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221.
35. Li JL, Hu SX, Zhou L, Ye L, Wang X, et al. (2011) Interferon Lambda Inhibits Herpes Simplex Virus Type I Infection of Human Astrocytes and Neurons. Glia 59: 58-67.
36. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, et al. (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 66: 1008-1014.
37. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100: 2610-2615.
38. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, et al. (2010) Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 62: 589-598.
39. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, et al. (2009) Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 10: 285-296.
40. Conrad B, (2003) Potential mechanisms of interferon-alpha induced autoimmunity. Autoimmunity 36: 519-523.
41. Levin MC, Lee SM, Kalume F, Morcos Y, Dohan FC, et al. (2002) Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 8: 509-513.
42. Kattan T, MacNamara A, Rowan AG, Nose H, Mosley AJ, et al. (2009) The avidity and lytic efficiency of the CTL response to HTLV-1. J Immunol 182: 5723-5729.
43. van Baarsen LGM, Kraan TCTMvdP, Kragt JJ, Baggen JMC, Rustenburg F, et al. (2006) A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 7: 522-531.
44. Pearlman BL, Traub N, (2011) Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Clin Infect Dis 52: 889-900.
45. Dhib-Jalbut S, Marks S, (2010) Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74: S17-S24.
46. Martin F, Taylor GP, (2011) Prospects for the management of human T-cell lymphotropic virus type 1-associated myelopathy. AIDS Rev 13: 161-170.
47. Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, et al. (2009) Stromal Cell-Mediated Suppression of Human T-Cell Leukemia Virus Type 1 Expression In Vitro and In Vivo by Type I Interferon. J Virol 83: 5101-5108.
48. Matsuoka M, Jeang K-T, (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7: 270-280.
49. Grassmann R, Aboud M, Jeang KT, (2005) Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24: 5976-5985.
50. Basbous J, Arpin C, Gaudray G, Piechaczyk M, Devaux C, et al. (2003) The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem 278: 43620-43627.
51. Matsumoto J, Ohshima T, Isono O, Shimotohno K, (2005) HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. Oncogene 24: 1001-1010.
52. Arnold J, Yamamoto B, Li M, Phipps AJ, Younis I, et al. (2006) Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 107: 3976-3982.
53. Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, et al. (2009) In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 6: 19.
54. Feng X, Ratner L, (2008) Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virology 374: 210-216.
55. Charoenthongtrakul S, Zhou Q, Shembade N, Harhaj NS, Harhaj EW, (2011) Human T cell leukemia virus type 1 Tax inhibits innate antiviral signaling via NF-kappaB-dependent induction of SOCS1. J Virol 85: 6955-6962.
56. Meek DW, (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723.
57. Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, et al. (2008) The HTLV-1 Tax interactome. Retrovirology 5: 76.
58. Akagi T, Ono H, Tsuchida N, Shimotohno K, (1997) Aberrant expression and function of p53 in T-cells immortalized by HTLV-I Tax1. FEBS Lett 406: 263-266.
59. Chandhasin C, Ducu RI, Berkovich E, Kastan MB, Marriott SJ, (2008) Human T-cell leukemia virus type 1 Tax attenuates the ATM-mediated cellular DNA damage response. J Virol 82: 6952-6961.
60. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, et al. (2005) Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry A 67A: 4-17.
61. Lee B, Tanaka Y, Tozawa H, (1989) Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I. Tohoku J Exp Med 157: 1-11.
62. Tanaka Y, Lee B, Inoi T, Tozawa H, Yamamoto N, et al. (1986) Antigens related to three core proteins of HTLV-I (p24, p19 and p15) and their intracellular localizations, as defined by monoclonal antibodies. Int J Cancer 37: 35-42.